Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
J Racial Ethn Health Disparities. 2024 Aug;11(4):2407-2415. doi: 10.1007/s40615-023-01706-2. Epub 2023 Jul 11.
Studies demonstrate higher mortality rates from colon cancer in American Indian/Alaskan Native (AI/AN) patients compared to non-Hispanic White (nHW). We aim to identify factors that contribute to survival disparities.
We used the National Cancer Database to identify AI/AN (n = 2127) and nHW (n = 527,045) patients with stage I-IV colon cancer from 2004 to 2016. Overall survival among stage I-IV colon cancer patients was estimated by Kaplan-Meier analysis; Cox proportional hazard ratios were used to identify independent predictors of survival.
AI/AN patients with stage I-III disease had significantly shorter median survival than nHW (73 vs 77 months, respectively; p < 0.001); there were no differences in survival for stage IV. Adjusted analyses demonstrated that AI/AN race was an independent predictor of higher overall mortality compared to nHW (HR 1.19, 95% CI 1.01-1.33, p = 0.002). Importantly, compared to nHW, AI/AN were younger, had more comorbidities, had greater rurality, had more left-sided colon cancers, had higher stage but lower grade tumors, were less frequently treated at an academic facility, were more likely to experience a delay in initiation of chemotherapy, and were less likely to receive adjuvant chemotherapy for stage III disease. We found no differences in sex, receipt of surgery, or adequacy of lymph node dissection.
We found patient, tumor, and treatment factors that potentially contribute to worse survival rates observed in AI/AN colon cancer patients. Limitations include the heterogeneity of AI/AN patients and the use of overall survival as an endpoint. Additional studies are needed to implement strategies to eliminate disparities.
研究表明,与非西班牙裔白人(nHW)相比,美洲印第安人/阿拉斯加原住民(AI/AN)患者的结肠癌死亡率更高。我们旨在确定导致生存差异的因素。
我们使用国家癌症数据库,从 2004 年至 2016 年期间,确定了患有 I-IV 期结肠癌的 AI/AN(n=2127)和 nHW(n=527045)患者。通过 Kaplan-Meier 分析估计 I-IV 期结肠癌患者的总生存率;使用 Cox 比例风险比确定生存的独立预测因素。
患有 I-III 期疾病的 AI/AN 患者的中位生存期明显短于 nHW(分别为 73 个月和 77 个月;p<0.001);IV 期无生存差异。调整后的分析表明,与 nHW 相比,AI/AN 种族是总死亡率更高的独立预测因素(HR 1.19,95%CI 1.01-1.33,p=0.002)。重要的是,与 nHW 相比,AI/AN 患者年龄更小,合并症更多,农村地区更多,左侧结肠癌更多,肿瘤分期更高但分级更低,在学术医疗机构接受治疗的可能性更低,更有可能延迟开始化疗,且接受 III 期疾病辅助化疗的可能性更低。我们发现性别、手术接受情况或淋巴结清扫充分性方面无差异。
我们发现了一些可能导致 AI/AN 结肠癌患者生存率较差的患者、肿瘤和治疗因素。局限性包括 AI/AN 患者的异质性和使用总生存率作为终点。需要进一步的研究来实施消除差异的策略。